CD274 and neoplasm: At the 4-year follow-up, patients treated with nivolumab plus ipilimumab and chemotherapy continued to show a durable OS benefit over those treated with chemotherapy alone (21% versus 16%), regardless of tumor PD-L1 expression and/or histology [80].